Fujian Haixi Pharmaceuticals Co., Ltd. (HKG:2637)

Hong Kong · Delayed Price · Currency is HKD

175.60

+0.30 (0.17%)

Sep 23, 2026, 4:08 PM HKT

Market Cap	13.82B
Revenue (ttm)	685.64M +87.6%
Net Income	173.48M +27.9%
EPS	2.31 +14.3%
Shares Out	78.71M
PE Ratio	76.17
Forward PE	61.10
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40,000
Open	178.00
Previous Close	175.30
Day's Range	175.50 - 179.90
52-Week Range	97.50 - 302.40
Beta	n/a
Analysts	Strong Buy
Price Target	292.39 (+66.51%)
Earnings Date	Aug 28, 2026

About HKG:2637

Fujian Haixi Pharmaceuticals Co., Ltd. engages in research and development, production, and sale of pharmaceutical products in China. The company offers drugs for oncology, ophthalmology, respiratory, digestion, cardiovascular, endocrine, and nervous systems, and inflammation. It also provides pharmaceuticals technical services. In addition, the company offers generic alternatives, such as Anbili, a generic of mosapride citrate tablets; Haihuitong 5mg/10mg and 5mg/20mg, a generic of amlodipine besilate and atorvastatin calcium tablets; Ruiantuo... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2012

Employees 200

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2637

Full Company Profile

Financial Performance

In 2025, HKG:2637's revenue was 582.36 million, an increase of 24.79% compared to the previous year's 466.68 million. Earnings were 177.03 million, an increase of 30.09%.

Financial numbers in CNY Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 2637 stock is "Strong Buy." The 12-month stock price target is $292.39, which is an increase of 66.51% from the latest price.

Price Target

$292.39

(66.51% upside)

Analyst Consensus: Strong Buy

Stock Forecasts